Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04525352 · ClinicalTrials.gov registry record · Phase 1
A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis
A Phase 1 study, sponsored by Rocket Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04525352 is a Phase 1 study that was terminated before completion, run by Rocket Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT04525352, a Phase 1 study, was terminated before completion, sponsored by Rocket Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this Phase 1 study is to evaluate the therapeutic safety and feasibility of the investigational product (IP), RP-L401.
Interventions
- BIOLOGICAL RP-L401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-11-19 |
| Est. Completion | 2021-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04525352
The ClinicalTrials.gov registry entry for NCT04525352 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rocket Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RP-L401 is the first listed.
NCT04525352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04525352 about?
NCT04525352 is a clinical study titled "A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis". The primary objective of this Phase 1 study is to evaluate the therapeutic safety and feasibility of the investigational product (IP), RP-L401.
What is the current status of trial NCT04525352?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-11-19. Estimated completion is 2021-05-21.
What interventions are being tested in trial NCT04525352?
The interventions under investigation include: RP-L401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04525352?
This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.